Materiały źródłowe

• #1 Vasculitis: Symptoms, Types & Treatment

  https://my.clevelandclinic.org/health/diseases/12101-vasculitis

  You cant prevent vasculitis because experts dont know what causes it. Theres no way to know if someone will develop it. […] Your provider will suggest treatments that manage the symptoms youre experiencing. Theyll help you find treatments that prevent damage to your blood vessels and organs. Some medications your provider might prescribe include: Corticosteroids, Immunosuppressants or biologics, ACE inhibitors.

• #2 Vasculitis Guide: Causes, Symptoms and Treatment Options

  https://www.drugs.com/health-guide/vasculitis.html

  There is no way to prevent most forms of vasculitis. If a medication caused vasculitis, you may be able to prevent another case of vasculitis by avoiding that drug.

• #3 Necrotizing Vasculitis – UF Health

  https://ufhealth.org/conditions-and-treatments/necrotizing-vasculitis

  There is no known way to prevent this disorder.

• #4 Vasculitis – Causes and Risk Factors | NHLBI, NIH

  https://www.nhlbi.nih.gov/health/vasculitis/causes

  Can vasculitis be prevented? Some types of vasculitis cannot be prevented because they are caused by autoimmune disorders. However, depending on what caused the vasculitis, it is possible to prevent some types from flaring up. […] Your healthcare provider may prescribe medicines to reduce symptoms. […] Anticoagulant medicines prevent blood clots from forming. You may need them if you have an aneurysm. […] Beta blockers lower blood pressure. You may need them if you have an aneurysm. […] Statins control or lower high blood cholesterol levels and have anti-inflammatory effects. […] Your provider may also recommend healthy lifestyle changes. […] Adopt a heart-healthy lifestyle. […] Avoid illegal drugs, including cocaine. If you use illegal or street drugs, ask your healthcare provider how to get help to stop. […] Quit smoking and tobacco.

• #5 Vasculitis | Society for Vascular Surgery

  https://vascular.org/your-vascular-health/vascular-conditions/vasculitis

  There is no way to prevent vasculitis or protect against it. Its causes are not well understood and its severity, duration and affected area/organ system vary greatly. […] It is essential that you avoid cigarette smoking to decrease complications from vasculitis. […] Ask your vascular surgeon how to lower your risk of infections. […] Take medications as prescribed. […] See your vascular surgeon as recommended.

• #6 Vasculitis, Blood Vessel Inflammation | TGH

  https://www.tgh.org/institutes-and-services/conditions/vasculitis

  Vasculitis cannot be completely prevented because many of its triggers cannot be controlled. That said, there are several ways to reduce the risk of developing vasculitis and manage the condition effectively if it does develop. These include: […] Prompt detection and treatment of underlying health issues, such as infections and autoimmune conditions, can help prevent vasculitis. Regular medical check-ups and monitoring are essential, especially if there is a family history of autoimmune disease. […] Certain infections, such as those caused by bacteria or viruses, can trigger vasculitis in some people. Practicing proper hygiene and receiving appropriate vaccinations can help reduce the risk. It is also important to promptly treat any infections that do develop. […] If an autoimmune disease is diagnosed, a health care provider can suggest an appropriate management strategy to help reduce the likelihood of developing vasculitis.

• #7 Vasculitis: Types, Symptoms, Causes, Diagnosis, Treatment and More

  https://www.health.com/vasculitis-8348465

  How to Prevent Vasculitis Flares […] Like most autoimmune conditions, there is no surefire way to prevent vasculitis. However, following your treatment plan, seeing your healthcare provider regularly, and adopting healthy lifestyle habits can help control inflammation and reduce the frequency and severity of symptom flare-ups. The following may help prevent vasculitis flares: […] Eat a nutritious, balanced diet […] Participate in exercise or physical activity daily […] Get plenty of sleep […] Manage stress through activities such as yoga, meditation, or breathwork […] Quit smoking […] Avoid excess alcohol consumption […] Stay up-to-date on routine vaccinations, including COVID-19 and the flu […] […] […] The goal of treatment for vasculitis is to reduce inflammation in the blood vessels to achieve remission or, a period in which you have no symptoms. Early diagnosis and treatment can help prevent damage to organs and tissues.

• #8 Key Elements for Optimizing Care in People with Vasculitis

  https://consultqd.clevelandclinic.org/key-elements-for-optimizing-care-in-people-with-vasculitis

  Use of prophylactic and preventive strategies is important. Infection represents one of the greatest risks of the immunosuppressive agents used to treat vasculitis. Prophylaxis against Pneumocystis pneumonia should be given to patients receiving regimens known to place patients at increased risk of this opportunistic infection. […] Some medications have toxicities for which an effective prevention strategy exists. Examples include taking daily oral cyclophosphamide in the morning with a large amount of fluid to prevent urothelial toxicity or the use of folic acid with methotrexate. A recently updated ACR guideline for the prevention and treatment of glucocorticoid-induced osteoporosis was presented at ACR Convergence 2022.

• #9 Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis – PubMed

  https://pubmed.ncbi.nlm.nih.gov/25627555/

  We suggest to routinely prescribe trimethoprim-sulfamethoxazole or antimicrobial agents such as pentamidine in case of intolerance or contraindication in the early phase of induction therapy irrespective of the immunosuppressive strategy used and to continue therapy, together with other targeted measures (antiviral, antimycotic or antibiotic) in the presence of risk factors for a prolonged period of time. […] Finally, there is an urgent need to standardize the reporting of infectious complications in clinical trials to enable comparing the adverse event spectrum of distinct treatment approaches more appropriately.

• #10 Vasculitis and Thrombophlebitis Follow-up: Further Outpatient Care, Transfer, Deterrence/Prevention

  https://emedicine.medscape.com/article/1008239-followup

  Primary prevention of systemic vasculitis is not usually possible. […] One must maintain a high index of suspicion for this group of diseases because early diagnosis and appropriate aggressive treatment is essential. […] Prevention of renal disease in Henoch-Schnlein purpura has been an area of controversy in the literature. Treatment with corticosteroids may prevent progression of renal disease; however, a true benefit has not been proven. […] Prophylaxis for P jiroveci with trimethoprim-sulfamethoxazole is indicated for patients being treated with cyclophosphamide. […] All patients receiving prednisone should have monitoring of bone mineral density and should ensure good intake of calcium and vitamin D. […] Secondary thromboprophylaxis indicated for patients with thrombotic event and hypercoagulable state/antiphospholipid antibody syndrome.

• #11 Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis | Annals of the Rheumatic Diseases

  https://ard.bmj.com/content/77/10/1440

  Trimethoprimsulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis […] The prophylactic use of trimethoprimsulfamethoxazole was associated with a lower frequency of severe infections (HR 0.30, 95%CI 0.13 to 0.69) […] Trimethoprimsulfamethoxazole prophylaxis reduced the risk, while especially bronchiectasis and endobronchial involvement are risk factors for severe respiratory infections […] Antibiotic prophylaxis to prevent P. jirovecii infections with trimethoprimsulfamethoxazole reduced the risk of severe infections (HR 0.45, 95%CI 0.23 to 0.88) […] A multivariate logistic regression analysis revealed that the use of trimethoprimsulfamethoxazole as prophylactic antibiotic measure had an impact on reduction of severe infections (HR 0.30, 95%CI 0.13 to 0.69) […] Thus, it may be appropriate to conclude that trimethoprimsulfamethoxazole may reduce P. jirovecii pneumonia and also reduces overall infective risk and prophylaxis should be initiated in patients with AAV receiving rituximab.

• #12 Managing ANCA-associated vasculitis – The Pharmaceutical Journal

  https://pharmaceutical-journal.com/article/ld/managing-anca-associated-vasculitis

  All patients receiving induction therapies should be given the oral antibiotic co-trimoxazole as prophylaxis against Pneumocystis jirovecii pneumonia (dapsone, atovaquone or nebulised pentamidine can be used if contraindicated), and the antifungal fluconazole should be considered to minimise the risk of oral and invasive candidiasis. […] Prophylaxis against steroid-induced osteoporosis should also be offered according to national guidelines.

• #13

  https://link.springer.com/article/10.1007/s40674-017-0082-y

  Successful therapy should focus on suppressing disease activity and minimising treatment-related toxicity. […] Annual pneumococcal and influenza vaccinations, Pneumocystis jiroveci prophylaxis and tuberculosis (TB) and Hepatitis B virus screening are advised. […] Prophylaxis with co-trimoxazole (800/160 mg on alternate days or 400/80 mg daily) is recommended for all patients undergoing cyclophosphamide or rituximab treatment. […] Vaccination should be used to reduce the risk of respiratory infections. […] Current British Society of Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidance recommends that all AAV patients require a thorough history, clinical examination and chest X-ray to screen for TB before commencing immunosuppressive therapy. TB prophylaxis is then indicated if latent TB is detected.

• #14 Preventive Antibiotics in AAV May Reduce Risk of Severe Infections | Treatment May Help Vasculitis Patients on Immunosuppressives | ANCA Vasculitis NewsEnvelope icon

  https://ancavasculitisnews.com/news/preventive-antibiotics-aav-may-reduce-risk-severe-infections/

  Preventive, or prophylactic treatment with certain antibiotics can reduce the risk of severe infections for people with ANCA-associated vasculitis (AAV) who are receiving immunosuppressive treatment, a new analysis shows. […] Since infections are one of the leading causes of death in patients with AAV, strategies to prevent or minimize infections are of importance, the researchers wrote. […] Due to the risk of infection, some therapy guidelines recommend that AAV patients who are starting on them should be given preventive treatment with bacteria-killing antibiotics. […] Statistical models showed that the risk of severe infection was significantly lower, by nearly 80%, in patients given TMP/SMX, compared with those who did not receive this prophylaxis. These results “reveal a significant benefit” for prophylactic TMP/SMX in AAV patients undergoing immunosuppressive treatment, the researchers wrote. […] Based on these findings, the team noted that the benefits of this preventive antibiotics treatment may extend beyond only preventing certain forms of pneumonia.

• #15 EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update | Annals of the Rheumatic Diseases

  https://ard.bmj.com/content/83/1/30

  C. Patients with AAV should be periodically screened for treatment-related adverse effects and comorbidities. We recommend prophylaxis and lifestyle advice to reduce treatment-related complications and other comorbidities. […] This highlights the importance of shared decision-making between patients and physicians. Adherence to effective therapies is crucial to prevent permanent organ damage related to uncontrolled inflammation in AAV. Therefore, the committee considers efficacy, safety and tolerability as important factors in the decision-making process. This includes other factors such as kidney or liver function, fertility and pregnancy, lifestyle/smoking habits or concomitant interacting medications. Costs of treatment also need to be considered as access to expensive medication may be restricted in some countries. […] 17. For patients with AAV receiving RTX, CYC and/or high doses of GCs, we recommend the use of T/S as prophylaxis against Pneumocystis jirovecii pneumonia (PJP) and other infections.

• #16 Systemic Vasculitis | AAFP

  https://www.aafp.org/pubs/afp/issues/2011/0301/p556.html

  Vitamin D and calcium prophylaxis are recommended in patients on long-term steroid therapy. […] Recommendations regarding detecting and preventing these complications include use of mesna (Mesnex) for protecting against urothelial toxicity of cyclophosphamide, antifungal prophylaxis, prophylaxis against Pneumocystis jiroveci, consideration for Staphylococcus aureus treatment, screening for cervical malignancy, and counseling about infertility with cyclophosphamide. […] Bisphosphonate Bone protection with long-term steroid.

• #17

  https://link.springer.com/article/10.1007/s40674-017-0082-y

  Guidelines recommend that hepatitis B surface antigen (HBsAg)-positive patients receive preemptive antiviral therapy before starting therapy and that hepatitis B core antibody (HBcAb)-positive patients should be considered for preemptive antiviral therapy if rituximab or cyclophosphamide are given. […] It is also advisable to consider prophylactic gastric protection for AAV patients receiving a prolonged course of high-dose corticosteroids due to the risk of mucosal irritation. […] Until the development of treatments without the significant side effects that still remain from current regimens, we need to focus on prophylaxis to prevent the known toxicity from AAV therapies.

• #18 Thrombosis in vasculitis: from pathogenesis to treatment | Thrombosis Journal | Full Text

  https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-015-0047-z

  In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected. […] These findings have important consequences in terms of management and treatment. Indeed, Behetsyndrome requires immunosuppressive agents for vascular involvement rather than anticoagulation or antiplatelet therapy, and it is conceivable that also in ANCA-associated vasculitis or large vessel-vasculitis an aggressive anti-inflammatory treatment during active disease could reduce the risk of thrombotic events in early stages. […] The management of vascular thrombosis in BS patients is based on immunosuppressive therapy to reduce the inflammation of the vessel wall. Anti-inflammatory treatments are able to promote a rapid and effective regression of the vascular lesions, to prevent the extension of thrombosis and its recurrence.

• #19 Thrombosis in vasculitis: from pathogenesis to treatment | Thrombosis Journal | Full Text

  https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-015-0047-z

  Usually, anticoagulants alone are not recommended in BS patients. […] The pathophysiology of thrombosis in BS, where systemic inflammation promotes the prothrombotic state leading to the formation of a thrombus tightly adherent to the vessel wall with a low rate of embolism, the discordant data on coagulation abnormalities, the possibility of the coexistence of PAA and thrombosis and the low efficacy of the anticoagulants reported in several studies are the main reasons that support the treatment with immunosuppressive agents and not with anticoagulants in BS patients. […] Nowadays, conflicting data exist about the role of antiplatelet/anticoagulant therapy in LVV, while their role in AAV is obscure.

• #20 Vasculitis and Thrombophlebitis Follow-up: Further Outpatient Care, Transfer, Deterrence/Prevention

  https://emedicine.medscape.com/article/1008239-followup

  Primary prevention of systemic vasculitis is not usually possible. […] One must maintain a high index of suspicion for this group of diseases because early diagnosis and appropriate aggressive treatment is essential. […] Prevention of renal disease in Henoch-Schnlein purpura has been an area of controversy in the literature. Treatment with corticosteroids may prevent progression of renal disease; however, a true benefit has not been proven. […] Prophylaxis for P jiroveci with trimethoprim-sulfamethoxazole is indicated for patients being treated with cyclophosphamide. […] All patients receiving prednisone should have monitoring of bone mineral density and should ensure good intake of calcium and vitamin D. […] Secondary thromboprophylaxis indicated for patients with thrombotic event and hypercoagulable state/antiphospholipid antibody syndrome.

• #21 Thrombosis in vasculitis: from pathogenesis to treatment | Thrombosis Journal | Full Text

  https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-015-0047-z

  In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected. […] These findings have important consequences in terms of management and treatment. Indeed, Behetsyndrome requires immunosuppressive agents for vascular involvement rather than anticoagulation or antiplatelet therapy, and it is conceivable that also in ANCA-associated vasculitis or large vessel-vasculitis an aggressive anti-inflammatory treatment during active disease could reduce the risk of thrombotic events in early stages. […] The management of vascular thrombosis in BS patients is based on immunosuppressive therapy to reduce the inflammation of the vessel wall. Anti-inflammatory treatments are able to promote a rapid and effective regression of the vascular lesions, to prevent the extension of thrombosis and its recurrence.

• #22 Cutaneous small vessel vasculitis

  https://dermnetnz.org/topics/cutaneous-small-vessel-vasculitis

  Flares of cutaneous small vessel vasculitis can be minimised by rest, compression and elevation of lower legs. […] Once a drug is identified as the cause of small vessel vasculitis, the patient should avoid it lifelong. It is not usually possible to prevent other forms of vasculitis.

• #23 Exercise-induced vasculitis

  https://dermnetnz.org/topics/exercise-induced-vasculitis

  Management of exercise-induced vasculitis involves: […] Compression stockings to relieve discomfort and speed up healing. They may possibly help prevent exercise-induced vasculitis. […] Patients with recurrent episodes of exercise-induced vasculitis should avoid vigorous exercise in warm weather.

• #24 Hypersensitivity vasculitis: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000874.htm

  Do not take medicines that have caused an allergic reaction in the past.

• #25 Vasculitis – Prevention, Diagnosis, and Management | WoundEducators.com

  https://woundeducators.com/vasculitis-prevention-diagnosis-and-management/?srsltid=AfmBOor8UAT02pZ-PKZ3afffIvBaawzPWZUr7IpP6Idsaiq8jVIUoOgO

  The first and preferred treatment for cutaneous vasculitis should always be avoidance of triggers known to exacerbate the condition, such as excessive standing, infection, or drugs. […] Treatment of vasculitis should begin with a confirmatory diagnosis to eliminate conditions with a similar appearance.

• #26 Vasculitis: Types, Symptoms, Causes, Diagnosis, Treatment and More

  https://www.health.com/vasculitis-8348465

  How to Prevent Vasculitis Flares […] Like most autoimmune conditions, there is no surefire way to prevent vasculitis. However, following your treatment plan, seeing your healthcare provider regularly, and adopting healthy lifestyle habits can help control inflammation and reduce the frequency and severity of symptom flare-ups. The following may help prevent vasculitis flares: […] Eat a nutritious, balanced diet […] Participate in exercise or physical activity daily […] Get plenty of sleep […] Manage stress through activities such as yoga, meditation, or breathwork […] Quit smoking […] Avoid excess alcohol consumption […] Stay up-to-date on routine vaccinations, including COVID-19 and the flu […] […] […] The goal of treatment for vasculitis is to reduce inflammation in the blood vessels to achieve remission or, a period in which you have no symptoms. Early diagnosis and treatment can help prevent damage to organs and tissues.

• #27 Vasculitis, Blood Vessel Inflammation | TGH

  https://www.tgh.org/institutes-and-services/conditions/vasculitis

  Consuming a balanced diet, engaging in regular physical activity and managing stress can help support a healthy immune system. Avoiding tobacco use and limiting alcohol consumption can further reduce the risk of developing vasculitis. […] In some cases, a physician may prescribe an immunosuppressive medication to manage immune system activity and help prevent inflammation that could trigger vasculitis. […] Vasculitis has been linked to certain harmful substances, so it is important to take steps to avoid exposure in the workplace and elsewhere.

• #28 Vasculitis medicationMédications – vasculites – Vasculitis Foundation Canada

  https://vasculitis.ca/?page_id=175

  There is no cure for Vasculitis. Treatment typically focuses on reducing discomfort and preventing serious complications. […] Although there is no cure for Vasculitis, people usually can control symptoms with proper medication, rest, exercise, and a healthy lifestyle. The goal of treatment is to reduce discomfort and prevent serious complications such. […] Please consult your doctor before starting on any medications. These are only guidelines and may not be suitable for each individual or each form of Vasculitis. […] Although rest is important during flares, doctors usually recommend moderate exercise, such as swimming or walking, when the symptoms have improved or disappeared. Exercise can help people with many forms of Vasculitis keep their joints strong and flexible.

• #29 Vasculitis and kidney disease | American Kidney Fund

  https://www.kidneyfund.org/all-about-kidneys/other-kidney-diseases/vasculitis-and-kidney-disease

  How can I prevent vasculitis from causing further kidney damage? If you have vasculitis, you may help prevent it from causing further kidney damage: […] Take your medicines as your doctor tells you […] Go to your doctor visits […] Get any tests your doctor recommends […] Talk to your doctor about any new or worsening symptoms […] Incorporate lifestyle changes, like following a healthy eating plan, being active, limiting alcohol, or quitting smoking or using tobacco.

• #30 Rheumatoid Vasculitis | Cedars-Sinai

  https://www.cedars-sinai.org/health-library/diseases-and-conditions/r/rheumatoid-vasculitis.html

  You may be able to reduce your risk for rheumatoid vasculitis by getting early, active treatment for your RA. Not smoking may also help reduce your risk. […] Contact your provider at the first sign of a vasculitis flare-up. Early treatment can help limit the severity of your symptoms. […] Quitting smoking may help you reduce your risk.

• #31 Medication for Vasculitis | NYU Langone Health

  https://nyulangone.org/conditions/vasculitis/treatments/medication-for-vasculitis

  Vasculitis is usually treatable with medication. After your NYU Langone rheumatologist has identified the type of vasculitis causing your symptoms, he or she works with you to develop a customized care plan to alleviate your symptoms and prevent further organ or tissue damage. […] Medication to reduce inflammation is the primary goal of most treatment for vasculitis. Your doctor may prescribe a combination of corticosteroids and immune-suppressing medications, which control inflammation. […] To maintain remission, many people take immunosuppressants with or without steroids for several years.

• #32 Vasculitis Program: Treatments & Services | Massachusetts General Hospital

  https://www.massgeneral.org/medicine/rheumatology/treatments-and-services/vasculitis

  Our experts aim to establish prompt diagnosis and implement early treatment plans that can induce remission and prevent relapse of vasculitis in the long term. […] To maximize the effectiveness of vasculitis treatment and to minimize medication side effects, our approach relies on developing a personalized treatment plan for each patient.

• #33 EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update | Annals of the Rheumatic Diseases

  https://ard.bmj.com/content/83/1/30

  C. Patients with AAV should be periodically screened for treatment-related adverse effects and comorbidities. We recommend prophylaxis and lifestyle advice to reduce treatment-related complications and other comorbidities. […] This highlights the importance of shared decision-making between patients and physicians. Adherence to effective therapies is crucial to prevent permanent organ damage related to uncontrolled inflammation in AAV. Therefore, the committee considers efficacy, safety and tolerability as important factors in the decision-making process. This includes other factors such as kidney or liver function, fertility and pregnancy, lifestyle/smoking habits or concomitant interacting medications. Costs of treatment also need to be considered as access to expensive medication may be restricted in some countries. […] 17. For patients with AAV receiving RTX, CYC and/or high doses of GCs, we recommend the use of T/S as prophylaxis against Pneumocystis jirovecii pneumonia (PJP) and other infections.

• #34 Maintenance therapy in well-controlled vasculitis: Is it ever ok to stop? • Johns Hopkins Rheumatology

  https://www.hopkinsrheumatology.org/2018/07/maintenance-therapy-in-well-controlled-vasculitis-is-it-ever-ok-to-stop/

  While most patients received maintenance therapy with low-dose steroids for some time after withdraw of immunosuppressive drugs, 3 did not and 15 were weaned completely off of steroids during the follow up period. […] This work strengthens the emerging view that select patients with ANCA-associated vasculitis may be able to come off immunosuppression completely and remain in remission. […] Our findings emphasize the importance of future studies to thoroughly characterize which patients would be able to successfully come off medication.

• #35 Medication for Vasculitis | NYU Langone Health

  https://nyulangone.org/conditions/vasculitis/treatments/medication-for-vasculitis

  Vasculitis is usually treatable with medication. After your NYU Langone rheumatologist has identified the type of vasculitis causing your symptoms, he or she works with you to develop a customized care plan to alleviate your symptoms and prevent further organ or tissue damage. […] Medication to reduce inflammation is the primary goal of most treatment for vasculitis. Your doctor may prescribe a combination of corticosteroids and immune-suppressing medications, which control inflammation. […] To maintain remission, many people take immunosuppressants with or without steroids for several years.

• #36 Maintenance therapy in well-controlled vasculitis: Is it ever ok to stop? • Johns Hopkins Rheumatology

  https://www.hopkinsrheumatology.org/2018/07/maintenance-therapy-in-well-controlled-vasculitis-is-it-ever-ok-to-stop/

  While most patients received maintenance therapy with low-dose steroids for some time after withdraw of immunosuppressive drugs, 3 did not and 15 were weaned completely off of steroids during the follow up period. […] This work strengthens the emerging view that select patients with ANCA-associated vasculitis may be able to come off immunosuppression completely and remain in remission. […] Our findings emphasize the importance of future studies to thoroughly characterize which patients would be able to successfully come off medication.

• #37 Vasculitis | UCSF Department of Surgery

  https://surgery.ucsf.edu/condition/vasculitis

  You can’t prevent vasculitis. However, treatment can help prevent or delay the complications of vasculitis. […] People who have severe vasculitis are treated with prescription medicines. Rarely, surgery may be done. People who have mild vasculitis may find relief with over-the-counter pain medicines, such as acetaminophen, aspirin, ibuprofen, or naproxen.

• #38 Vasculitis Program: Treatments & Services | Massachusetts General Hospital

  https://www.massgeneral.org/medicine/rheumatology/treatments-and-services/vasculitis

  Our experts aim to establish prompt diagnosis and implement early treatment plans that can induce remission and prevent relapse of vasculitis in the long term. […] To maximize the effectiveness of vasculitis treatment and to minimize medication side effects, our approach relies on developing a personalized treatment plan for each patient.

• #39

  https://link.springer.com/article/10.1007/s40674-017-0082-y

  Guidelines recommend that hepatitis B surface antigen (HBsAg)-positive patients receive preemptive antiviral therapy before starting therapy and that hepatitis B core antibody (HBcAb)-positive patients should be considered for preemptive antiviral therapy if rituximab or cyclophosphamide are given. […] It is also advisable to consider prophylactic gastric protection for AAV patients receiving a prolonged course of high-dose corticosteroids due to the risk of mucosal irritation. […] Until the development of treatments without the significant side effects that still remain from current regimens, we need to focus on prophylaxis to prevent the known toxicity from AAV therapies.

• #40 Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? | Arthritis Research & Therapy | Full Text

  https://arthritis-research.biomedcentral.com/articles/10.1186/ar2826

  According to the EULAR recommendations, T/S prophylaxis is encouraged in all patients being treated with Cyc. […] Even though PCP is rare in large vessel vasculitis, the use of T/S prophylaxis in all PSV patients receiving GCs 15 mg per day and a GC-sparing immunosuppressant (for example, MTX) might be considered. […] However, the potential interaction of MTX and T/S has to be taken into account and strict folate substitution is mandatory. […] Infections significantly contribute to morbidity and mortality in PSV patients. There are three ways of targeting this problem: recognising and minimising risk factors, implementing prophylaxis where appropriate and ensuring early diagnosis and targeted therapy if infections occur.

Zobacz więcej